Ngā hua rapu - David M. Jackman

Whakamahine hua
  1. 1
    Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations

    Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations mā Elizabeth M Gaughan, Sarah K. Cryer, Beow Y. Yeap, David M. Jackman, Daniel B. Costa

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic <i>EGFR</i> Mutations Treated with Gefitinib or Erlotinib

    Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic <i>EGFR</i> Mutations Treated with Gefitinib or Erlotinib mā Stéphanie Héon, Beow Y. Yeap, Gregory Joseph Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, Bruce E. Johnson

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

    Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors mā Sarah B. Goldberg, Geoffrey R. Oxnard, Subba R. Digumarthy, Alona Muzikansky, David M. Jackman, Inga T. Lennes, Lecia V. Sequist

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs

    Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs mā W. Marston Linehan, Stephanie Cardarella, Christine Lydon, Suzanne E. Dahlberg, David M. Jackman, Pasi A. Jänne, Bruce E. Johnson

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab

    Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab mā Mizuki Nishinoa, Sarah K. Cryer, Yuka Okajim, Lynette M. Sholl, Hiroto Hatabu, Michael S. Rabin, David M. Jackman, Bruce E. Johnson

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI

    Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI mā Mizuki Nishino, Suzanne E. Dahlberg, Stephanie Cardarella, David M. Jackman, Michael S. Rabin, Hiroto Hatabu, Pasi A. Jänne, Bruce E. Johnson

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Pathologic Characteristics of NUT Midline Carcinoma Arising in the Mediastinum

    Pathologic Characteristics of NUT Midline Carcinoma Arising in the Mediastinum mā Andrew G. Evans, Christopher A. French, Michael J. Cameron, Christopher D.�M. Fletcher, David M. Jackman, Christopher S. Lathan, Lynette M. Sholl

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival

    Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival mā Mizuki Nishino, Stephanie Cardarella, Suzanne E. Dahlberg, Tetsuro Araki, Christine Lydon, David M. Jackman, Michael S. Rabin, Hiroto Hatabu, Bruce E. Johnson

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer

    Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer mā Peter Lo, Suzanne E. Dahlberg, Mizuki Nishino, Bruce E. Johnson, Lecia V. Sequist, David M. Jackman, Pasi A. Jänne, Geoffrey R. Oxnard

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors

    Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors mā Mizuki Nishino, Stephanie Cardarella, Suzanne E. Dahlberg, David M. Jackman, Nikhil H. Ramaiya, Hiroto Hatabu, Michael S. Rabin, Pasi A. Jnne, Bruce E. Johnson

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Outcomes After Combined Modality Therapy for<i>EGFR</i>-Mutant and Wild-Type Locally Advanced NSCLC

    Outcomes After Combined Modality Therapy for<i>EGFR</i>-Mutant and Wild-Type Locally Advanced NSCLC mā Raymond H. Mak, Elizabeth Doran, Alona Muzikansky, Josephine Kang, Joel W. Neal, Noah C. Choi, Henning Willers, David M. Jackman, Lecia V. Sequist

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

    Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions mā Geoffrey R. Oxnard, Peter Lo, Mizuki Nishino, Suzanne E. Dahlberg, Neal I. Lindeman, Mohit Butaney, David M. Jackman, Bruce E. Johnson, Pasi A. Jänne

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <i>EGFR</i> Wild-type Cancers

    Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <i>EGFR</i> Wild-type Cancers mā Kimio Yonesaka, Kreshnik Zejnullahu, Neal I. Lindeman, Alison J. Homes, David M. Jackman, Feng Zhao, Andrew M. Rogers, Bruce E. Johnson, Pasi A. Jänne

    I whakaputaina 2008
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    <i>EGFR</i>Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry

    <i>EGFR</i>Mutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry mā Lynette M. Sholl, Yun Xiao, Victoria A. Joshi, Beow Y. Yeap, Leigh‐Anne Cioffredi, David M. Jackman, Charles Lee, Pasi A. Jänne, Neal I. Lindeman

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

    Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma mā David M. Jackman, Hedy L. Kindler, Beow Y. Yeap, Panos Fidias, Ravi Salgia, Joan Lucca, Linda K. Morse, Patricia Ostler, Bruce E. Johnson, Pasi A. Jänne

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy

    New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Resp... mā Mizuki Nishino, David M. Jackman, Hiroto Hatabu, Beow Y. Yeap, Leigh‐Anne Cioffredi, Jeffrey T. Yap, Pasi A. Jänne, Bruce E. Johnson, Annick D. Van den Abbeele

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

    Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer mā David M. Jackman, William Pao, Gregory J. Riely, Jeffrey A. Engelman, Mark G. Kris, Pasi A. Jänne, Thomas J. Lynch, Bruce E. Johnson, Vincent A. Miller

    I whakaputaina 2009
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations

    The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations mā Stéphanie Héon, Beow Y. Yeap, Neal I. Lindeman, Victoria A. Joshi, Mohit Butaney, Gregory Joseph Britt, Daniel B. Costa, Michael S. Rabin, David M. Jackman, Bruce E. Johnson

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer

    The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer mā Stephanie Cardarella, Taylor M. Ortiz, Victoria A. Joshi, Mohit Butaney, David M. Jackman, David J. Kwiatkowski, Beow Y. Yeap, Pasi A. Jänne, Neal I. Lindeman, Bruce E. Johnson

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Response and Resistance in a Non–Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose Gefitinib

    Response and Resistance in a Non–Small-Cell Lung Cancer Patient With an Epidermal Growth Factor Receptor Mutation and Leptomeningeal Metastases Treated With High-Dose Gefitinib mā David M. Jackman, Alison J. Holmes, Neal I. Lindeman, Patrick Y. Wen, Santosh Kesari, Ana M. Borras, Christopher J. Bailey, Francisca de Jong, Pasi A. Jänne, Bruce E. Johnson

    I whakaputaina 2006
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: